{"prompt": "['No records may be disposed of without the written approval of the Sponsor. Written', 'notification should be provided to the Sponsor prior to transferring any records to another', 'party or moving them to another location.', '8.', 'ETHICAL CONSIDERATIONS', '8.1', 'COMPLIANCE WITH LAWS AND REGULATIONS', 'This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical', 'Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the', 'country in which the research is conducted, whichever affords the greater protection to the', 'individual. The study will comply with the requirements of the ICH E2A guideline (Clinical', 'Safety Data Management: Definitions and Standards for Expedited Reporting). Studies', 'conducted in the U.S. or under a U.S. Investigational New Drug (IND) application will comply', 'with U.S. FDA regulations and applicable local, state, and federal laws. Studies conducted in', 'the E.U. or European Economic Area will comply with the E.U. Clinical Trial Directive', '(2001/20/EC).', '8.2', 'INFORMED CONSENT', \"The Sponsor's sample Informed Consent Form (and ancillary sample Informed Consent\", \"Forms such as a Child's Informed Assent Form) will be provided to each site. If applicable, it\", 'will be provided in a certified translation of the local language. The Sponsor or its designee', \"must review and approve any proposed deviations from the Sponsor's sample Informed\", 'Consent Forms or any alternate consent forms proposed by the site (collectively, the', '\"Consent Forms\") before IRB/EC submission. The final IRB/EC-approved Consent Forms', 'must be provided to the Sponsor for health authority submission purposes according to local', 'requirements.', 'If applicable, the Informed Consent Form will contain separate sections for any optional', 'procedures. The investigator or authorized designee will explain to each patient the', 'objectives, methods, and potential risks associated with each optional procedure. Patients', 'will be told that they are free to refuse to participate and may withdraw their consent at any', \"time for any reason. A separate, specific signature will be required to document a patient's\", 'agreement to participate in optional procedures. Patients who decline to participate will not', 'provide a separate signature.', \"The Consent Forms must be signed and dated by the patient or the patient's legally\", 'authorized representative before his or her participation in the study. The case history or', 'clinical records for each patient shall document the informed consent process and that', 'written informed consent was obtained prior to participation in the study.', 'The Consent Forms should be revised whenever there are changes to study procedures or', 'when new information becomes available that may affect the willingness of the patient to', 'participate. The final revised IRB/EC-approved Consent Forms must be provided to the', 'Sponsor for health authority submission purposes.', 'Patients must be re-consented to the most current version of the Consent Forms (or to a', 'significant new information/findings addendum in accordance with applicable laws and', 'IRB/EC policy) during their participation in the study. For any updated or revised Consent', 'Emicizumab - F. Hoffmann-La Roche Ltd', '149 / Protocol MO39129, Version 3']['Forms, the case history or clinical records for each patient shall document the informed', 'consent process and that written informed consent was obtained using the updated/revised', 'Consent Forms for continued participation in the study.', \"A copy of each signed Consent Form must be provided to the patient or the patient's legally\", 'authorized representative. All signed and dated Consent Forms must remain in each', \"patient's study file or in the site file and must be available for verification by study monitors at\", 'any time.', '8.3', 'INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE', 'This protocol, the Informed Consent Forms, any information to be given to the patient, and', 'relevant supporting information must be submitted to the IRB/EC by the Principal', 'Investigator and reviewed and approved by the IRB/EC before the study is initiated.', 'In addition, any patient recruitment materials must be approved by the IRB/EC.', 'The Principal Investigator is responsible for providing written summaries of the status of the', 'study to the IRB/EC annually or more frequently in accordance with the requirements,', 'policies, and procedures established by the IRB/EC. Investigators are also responsible for', 'promptly informing the IRB/EC of any protocol amendments (see Section 9.6).', 'In addition to the requirements for reporting all adverse events to the Sponsor, investigators', 'must comply with requirements for reporting serious adverse events to the local health', 'authority and IRB/EC. Investigators may receive written IND safety reports or other', 'safety-related communications from the Sponsor. Investigators are responsible for ensuring', 'that such reports are reviewed and processed in accordance with health authority', 'requirements and the policies and procedures established by their IRB/EC, and archived in', \"the site's study file.\", '8.4', 'CONFIDENTIALITY', 'The Sponsor maintains confidentiality standards by coding each patient enrolled in the study', 'through assignment of a unique patient identification number. This means that patient names', 'are not included in data sets that are transmitted to any Sponsor location.', 'Patient medical information obtained by this study is confidential and may be disclosed to', 'third parties only as permitted by the Informed Consent Form (or separate authorization for', 'use and disclosure of personal health information) signed by the patient, unless permitted or', 'required by law.', \"Medical information may be given to a patient's personal physician or other appropriate\", \"medical personnel responsible for the patient's welfare, for treatment purposes.\", 'The aggregate results of any conducted research will be available in accordance with the', 'effective Roche policy on study data publication (see Section 9.5).', 'Data generated by this study must be available for inspection upon request by', 'representatives of national and local health authorities, Sponsor monitors, representatives,', 'and collaborators, and the IRB/EC for each study site, as appropriate.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '150 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}